NICE green light for Cablivi in rare blood-clotting disorder
Treatment recommended for acquired thrombotic thrombocytopenic purpura
Read Moreby Lucy Parsons | Nov 13, 2020 | News | 0
Treatment recommended for acquired thrombotic thrombocytopenic purpura
Read Moreby Selina McKee | Sep 8, 2020 | News | 0
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read Moreby Selina McKee | Jun 12, 2020 | News | 0
Trial data does not show whether adding Cablivi to standard care improves either length or quality of life over the long term, the Institute said
Read Moreby Anna Smith | Feb 7, 2019 | News | 0
The US Food and Drug Administration (FDA) has approved Sanofi’s Cablivi as the first treatment for adult patients with a rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP).
Read Moreby Anna Smith | Jan 10, 2019 | News | 0
Sanofi’s Cablivi has been linked with a 74% reduction in aTTP-related death in a Phase III trial published by the New England Journal of Medicine.
Read Moreby Selina McKee | Sep 3, 2018 | News | 0
Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Read Moreby Selina McKee | Jul 2, 2018 | News | 0
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
